SCHEMBL2393686

SCHEMBL2393686

NC(=O)C(F)c1ccccc1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.48
FGFR1 P11362 2/20 0.46
FGFR2 P21802 2/20 0.46
FGFR4 P22455 2/20 0.46
FGFR3 P22607 2/20 0.46
SRC P12931 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
KMT2A Q03164 2/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
PTPRC P08575 1/20 0.39
PTPRF P10586 1/20 0.39
PTPN1 P18031 1/20 0.39
CDC25B P30305 1/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 1/20 0.39
HNF4A P41235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391709 0.85 KMT2A (0.47) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2393361 0.84 MAOB (0.43) FGFR1FGFR3
SCHEMBL2391830 0.82 HSP90AA1 (0.45) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2395411 0.80 NPSR1 (0.46) KMT2APTPRCPTPN1ALDH1A1MEN1
SCHEMBL2395269 0.79 BCAT2 (0.55) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2392699 0.79 BCAT2 (0.55) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2395264 0.79 BCAT2 (0.55) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL5056664 0.78 BCAT2 (0.48) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2391809 0.78 BCAT2 (0.48) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL9890795 0.77 FGFR1 (0.46) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885FGFR1 294/4885FGFR2 139/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885FGFR1 294/4885FGFR2 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.